Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety

This clinical trial, a single-arm prospective study, aims to evaluate the efficacy and safety of liposomal amphotericin B (3-5 mg/kg/day) combined with posaconazole/isavuconazole in treating adult patients with malignant hematological diseases complicated by mucormycosis. The primary objectives are to determine the proportion of patients achieving complete or partial resolution of mucormycosis symptoms and to identify prognostic factors influencing survival outcomes. Participants will receive the combination therapy, undergo regular monitoring of symptoms, adverse events, and disease progression via radiological and laboratory assessments, and complete follow-up visits to track long-term survival. The study will analyze composite response rates, treatment-related adverse events, and survival data to refine therapeutic strategies for this high-risk population.

NCT Number	NCT07185503
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Mucormycosis in Hematologic Malignancies
Enrollment	60 participants
Start Date	2025-03-25
Primary Completion	2026-06 (estimated)
Study Completion	2027-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-22